Document:

Filed by Automated Filing Services Inc. (604) 609-0244 - Imvision Therapeutics Inc. - Exhibit 10.5

[NOTE TO READER: CERTAIN PORTIONS OF THIS AGREEMENT RELATING
TO ROYALTY INFORMATION HAVE BEEN REMOVED AND ARE THE SUBJECT OF A REQUEST FOR
CONFIDENTIAL TREATMENT SUBMITTED BY THE COMPANY TO THE SECURITIES EXCHANGE
COMMISSION (THE "COMMISSION") PURSUANT TO RULE 406 OF THE SECURITIES ACT OF
1933. THE PRICING INFORMATION HAS BEEN DISCLOSED TO THE COMMISSION IN CONNECTION
WITH THE REQUEST FOR CONFIDENTIAL TREATMENT.] 

EXHIBIT 10.5

Translation from German into English

Patent Purchasing Agreement 
and Backlicense
Agreement

between Productomics AG, Promenade 132 A, CH-7260 Davos-Dorf,
Switzerland 

- as Seller -

and ImVisioN GmbH, Feodor-Lynen Straße 5, D-30625 Hanover,
Germany 

- as Buyer -

Recitals

The Seller is hereby granted all rights of registration of
patents GB 0309345.7 and WO 2004/094639 A2 entitled “A recombinant Allergen”,
requiring the use of the Fel d1 recombined allergen (fusion molecule in field 1
chain 2 and chain 1) in the diagnosis and treatment of cat allergies.

The Buyer is a biotechnology company, dealing with the
development of immunization therapies in treating allergic diseases.

The parties intend to transfer the patent rights and in this
respect they agree upon the following.

§ 1         
Scope of Agreement

1.            
The Seller represents that it is the sole owner of the rights over the
registration of the UK patent GB 0309345.7 of 24/04/2003 with well-grounded
priority, and of patent WO 2004/094639 A2 of 22/04/2004 (see Appendix 1). The
right of sole owner arises out of a contract between the seller and the person
registering the patent, as indicated in Appendix 2. The scope of such patent
registration is the use of the Fel d1 recombined allergen in the diagnosis and
treatment of cat allergies. Such patent registration is at the beginning of the
legal patenting procedure.

2.            
The scope of this Agreement is the transfer of all industrial or intellectual
property rights devolving upon the Seller and assigned to the Buyer hereunder,
arising from the aforementioned registration of patent or parts thereof,
including all rights arising from the registration of patent as well as from the
patents granted for all designated contractual states (hereinafter “contractual
rights”). The contractual rights include in particular all rights entitling the
Buyer to use and exploit in any way the registered invention.

1

3.            
For the purposes of this Agreement, the products are those manufactured by use
of contractual rights.

§ 2         
Transfer of contractual rights

1.            
The Seller hereby transfers the contractual rights to the Buyer, effective as of
31/01/2005. The parties agree that all rights over contractual rights, including
over the national patents granted in each of the contractual states specified
hereinafter, shall devolve upon the Buyer.

2.            
Immediately after the signing of this Agreement, the Seller shall take all
necessary formal steps for the transfer of the contractual rights to the Buyer
and registration thereof, including giving its consent to such registration, and
shall deliver the registration approvals as required.

3.            
The Seller shall deliver to the Buyer all original documents regarding the
contractual rights, in particular the patent deeds and all related documents,
required for obtaining and using the contractual rights. The Seller is entitled
to make copies of such documents in advance, for personal purposes.

4.            
Furthermore, the Seller shall supply orally or in writing all necessary
information for the Buyer to use the contractual rights.

5.            
The Seller represents as of now that, to this date, the documents and
information provided by the latter on the due delivery date, are accurate and
consistent with the facts set forth herein.

§ 3         
Further developments

1.            
If further technology developments underlying the contractual rights are
registered by the Seller or by the inventors specified in the patent
registration as protection rights, or give rise to a protection right over them,
the Seller hereby grants to the Buyer the option to also acquire the rights
arising from such registration of protection right, against an amount to be
mutually agreed upon. Such fee shall not exceed the value of patent fees set
hereinafter under § 6.

§
4           Backlicensing from
Buyer to Seller 

1.            
The Buyer grants to the Seller an exclusive license worldwide for the exclusive
use of the contractual rights in the field of diagnosis, with no further payment
obligations of the Seller to the Buyer.

2.            
The Seller is entitled to grant sublicenses to third parties, for the exclusive
use of the contractual scope in the field of diagnosis.

§
5           The Seller’s
indemnity

1.            
The parties agree on the following legal properties of the contractual
scope:
- the contractual rights consist of the volume specified herein and
are not affected by third party claims. In particular, there is no pending
dispute or dispute to be expected over the protection right, to the best
knowledge of the Buyer; 
- no technology status, contradictory to the
contractual rights with respect to the ongoing registrations of protection
rights, or with respect to scientific publications, scientific lectures, press
releases and other publications, published before the priority date of patent
registration, is known to the Seller in good faith. In particular, from the
investigations the latter conducted, it follows that there were no publications
that, in the opinion of its attorneys in the patent field, might endanger
nationwide and abroad the creation of registered protection rights;

2

- the data in the registration of the protection right
submitted to the Buyer are unchanged. Any changes further to the conclusion of
this Agreement require the Buyer’s consent; 
- the data in the registration
of the protection right are accurate and complete;
 - the previous rights of
use of third parties are not known to the Seller to the best of its knowledge.
No third party was involved in patent development apart from the inventors
specified in the patent deeds. The knowledge of third parties not publicly known
was not used

2.            
For this transfer of contractual rights, the Seller is liable under the law.

§ 6         
Patent fees

1.            
Fee calculation 

a)            
Lump sum fee

     For the transfer of the
contractual rights, the Buyer shall pay to the Seller a lump sum fee amounting
to 

	  	EUR 20,000.- 
	Such fee is due upon conclusion hereof. 	  
	  	  
	b)            
      Milestone payments 	  
	 	  
	The Buyer shall also make in favor of the Seller the
      following single payments upon completion of 	 
	each milestone: 	  
	(1) the European Office for Patents granting a patent 	  
	 	EUR 20,000.- 
	(2) beginning of a stage II clinical trial on a product 	  
	 	EUR 50,000.- 
	(3) beginning of a stage III clinical trial on a product
	EUR 100,000.- 
	 	  
	(4) registration for authorization of a product, in maximum
      total amount 	EUR 150,000.- 
	           
      with the FDA 	EUR 150,000.- 
	           
      in other countries outside the US, for each country 	EUR 25,000.- 
	 	  
	(5) Product authorization, in maximum total amount 	EUR 500,000.- 
	           
      by the FDA 	EUR 500,000.- 
	           
      by a regulatory authority in 	  
	           
      countries outside the US, for each authority 	EUR 100,000.-. 

For clarification purposes: in case of registration and
authorization by the FDA, if the maximum amounts of Euro 150,000 for
registration and Euro 500,000, respectively, for authorization by other
authorities have already been reached. If such maximum amounts have not been
reached, upon registration or authorization by the FDA, the balances shall be
paid until the maximum amounts are reached.

Milestone payments are due 30 days as of completion. But if a
(2) to (5) milestone is reached before a (1) milestone, due payments shall be
deferred until the (1) milestone is completed and shall be made with the payment
for the (1) milestone.

c)            
Sales tax (sales of products)

Furthermore, the Buyer shall pay to the Seller a sales tax.
This tax shall be calculated based on the net selling prices obtained by the
Buyer from the sale of products in the countries holding the patent, or where
the patent has been registered and not yet finally rejected, and where the
product might impair 

3

the patent. The net selling price is the selling price for
third parties, minus the discount and additional costs invoiced separately, such
as for transport, packaging, customs duties or other taxes. Discount and credit
payments or discounts for withdrawn or defective products shall not be deducted
from the net invoice value.

The following percentages are applicable: 

	(1) 	
      [***]% of the net selling price for annual sales
      below EUR 50 million

	(2) 	
      [***]% of the net selling price for annual sales
      of EUR 50 to 200 million

	(3) 	
      [***]% of the net selling price for annual sales
      above EUR 200 million.

[***OMITTED AND FILED SEPARATELY WITH THE COMMISSION
FURTHER TO A REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933]

2.            
Settlement and payment

a)             The
  Buyer draws up on a quarterly basis a settlement account for the license fees
  per sale, within 60 days as of the end of the quarter. 

  b)             The
  fees are due on the same date as the settlements specified above. In case of
  delay, on the receivable value a monthly interest of 3% above 3 months’
  LIBOR shall be calculated on June 30th of the relevant calendar year.
  

  c)             If
  license fees are subject to VAT payment, the Buyer also owes the related VAT.

§
7           Patenting
procedure and patent preservation

1.            
The patenting procedure devolves upon the Buyer. In particular, the Buyer is
free not to initiate the procedure at all, if and to the extent protection
claims deriving from the issue of the patent for the manufacturing of products
no longer interests the Buyer. In such case, the Buyer is entitled to terminate
this Agreement subject to a one month’s prior notice, and thus the Buyer shall
pass the contractual rights on the Seller, by the effective date of termination,
and shall exercise all due diligence in this respect. This clause can also be
applied for the conduct of clinical trials and product authorization.

2.            
The Buyer undertakes to maintain and preserve the granted patents.

3.            
In case the Buyer decides to no longer maintain its patent rights in a certain
country, it shall promptly inform the Seller that, in its turn, in order to take
over the necessary costs for maintaining the patent rights may require the Buyer
to maintain the patent. The Buyer’s obligation to pay the sales tax as per § 6.1
c) hereunder remains unaffected.

4.            
The aforementioned provisions are also valid for protection rights in other
commercial fields that may arise out of the contractual scope.

§
8           Application
of patent rights

1.          
The Seller undertakes to promptly inform the Buyer on any possible infringement
of protection rights by third parties or on any threat of such infringement,
that it may become aware of.

2.            
The Buyer shall, at its discretion, decide on the application of patent rights.
The Buyer shall cover all expenses related thereto.

3.            
The Seller undertakes to support the Buyer, at the latter’s request, in the
application of patent rights. The expenses thus incurred for the Seller shall be
covered by the Buyer, as it previously agreed thereupon with the Seller. Any
possible claims to damages or possible receipts obtained with a view to a deed
of arrangement shall devolve upon the Buyer.

4

4.            
The Seller undertakes not to personally challenge or help third parties to
challenge the patent rights. The Seller undertakes to bind, in its turn, by
contract the inventors specified in the patent registration, not to challenge
them.

§ 9         
Confidentiality

1.            
The contracting parties mutually undertake to keep the confidentiality of all
information and knowledge exchanged or to be exchanged prior and throughout this
Agreement relating to bases, modus operandi, construction, developments,
improvements, purchasing prices, license terms and other details regarding the
contractual rights and performance hereof.

2.            
The Buyer is entitled to publish a press release on the execution of this
Agreement. 

3.            
This obligation of confidentiality shall also govern the employees of the
contracting parties, to the extent they deal with the contractual rights. The
Seller is bound to take all necessary measures to ensure confidentiality is
being kept, to prevent and impede the unlawful disclosure of trading secrets
through its employees or other persons. This obligation of confidentiality for
employees should also govern the latter for the period subsequent to termination
of their respective employment contracts. The obligation should be imposed in
writing and submitted to the Buyer, upon request.

4.            
If either of the contracting parties finds that confidential documents or
trading secrets have been disclosed by third parties or associates of the Seller
or of the Buyer, or that the obligation of confidentiality has been breached by
other third parties with respect to documents, such party shall inform the other
party thereon.

5.            
The obligation of confidentiality shall survive the termination of this
Agreement.

6.            
For any case of default, the Buyer and the Seller shall be subject to a
contractual penalty in favor of the other party amounting to EURO 50,000.- per
case. Regardless thereof, the Seller or the Buyer can additionally claim from
the other party indemnities for any damage inflicted based on evidence. The
contractual penalty shall be calculated according to the extent of the
damage.

7.            
An exception to the aforementioned obligation is the disclosure of information
by the Seller under the backlicense as per § 4 paragraph 2. In such case, the
Seller is bound to impose on the sublicense holder the confidentiality clause
set forth above.

§ 10        Force
majeure

1.            
If either of the contracting parties fails to perform its contractual
obligations due to force majeure events, no right to damages shall arise
wherefrom for the other party, regardless of the legal grounds.

2.            
Force majeure events include in particular wars, internal commotion, terrorist
acts, seizure or other acts of the public power, failure of the authorities to
grant approvals (unless caused through the negligence or fault of the Buyer or
Seller), strikes, industrial conflicts of any nature, general shortage of raw
material, auxiliary and functional materials, natural phenomena or other
circumstance, which cannot be accounted for by the parties and can be removed
only with unexpected efforts, as well as undue late deliveries of materials or
limitations of public power supply.

§ 11        Contractual
term / Termination

1.            
This Agreement shall become effective on the signing date thereof and shall be
concluded for an indefinite period of time.

5

2.            
Whenever the Buyer defaults on any obligation hereunder, the Seller is entitled
to terminate this Agreement, unless such default on the contractual obligations
and its consequences are not immediately remedied, namely, within 60 days as of
request.

3.            
Whenever the Seller defaults on any obligation hereunder, the Buyer is entitled
to terminate this Agreement, unless such default on the contractual obligations
and its consequences are not immediately remedied, namely, within 60 days as of
request.

4.            
The right to extraordinary termination for material reasons remains
unaffected.

5.            
Termination shall be made in writing. If the termination is notified by a
registered letter, this is deemed as received even when the delivery attempt
failed and a delivery/acceptance message was left for the recipient.

6.            
If termination takes place for the reasons set forth above, the other party is
not entitled to claim damages. 

§ 12       Other
clauses

1.            
Setoff, assignment, waiver

a)            
The Seller can set off with setoff receivables, only if the latter are
acknowledged or legally ascertained by the Buyer.

b)            
The Seller is entitled to assign to third parties its rights and obligations
hereunder, subject to the Buyer’s approval. The Buyer shall not unreasonably
withhold its
approval. 
c)            
If either of the contracting parties fails to exercise any of its rights
hereunder, this shall not mean a waiver to such right.

2.            
Applicable law, place of performance

a)            
This Agreement is governed by the German Law.

b)            
The place of performance and the court venue for all obligations hereunder is
the Buyer’s registered office.

3.            
Contractual documents, contents, notices

a)             The
  contractual scope hereof is finally set out under this Agreement, along with
  its appendices and references. Appendices are integral part hereof. Apart from
  them, there are no other agreements between the parties. Any possible prior
  agreements shall have no scope. 

  b)             Headings
  are for layout purposes only and shall not permanently determine the contents
  of their respective texts. 

  c)             Any
  addenda, additions and amendments to this Agreement should be made in writing,
  unless other legal formal requirements apply. This also applies to the cancellation
  of this written format clause. 

  d)             Any
  notices to either contracting party should be sent to the following addresses.
  Amendments shall be considered, only if notified in writing to the declaring
  contracting party, or if the latter makes use of the changed address of the
  recipient.

	Seller: 	Dr. Jur. Hansjörg Kistler 
	  	Chairman of the Board of Directors 
	  	Productomics AG 
	  	Promenade 132A 
	  	CH-7260 Davos-Platz 
		Switzerland

6

	Buyer: 	Dr. Martin Steiner 
	  	General Manager 
	  .	ImVisioN GmbH 
	  	Feodor-Lynen Straße 5 
	  	D-30625 Hannover 
	  	Germany 

4.            
Costs, taxes

a)            
The costs for the execution and legal enforcement of this document shall be
borne by the Buyer.

b)            
Consulting costs related to the conclusion or performance hereof shall be
covered by each party for itself. If, at the request of either of the
contracting parties, consulting or other services are provided by third parties,
such contracting party shall pay the relevant fees to the third parties.

c)            
The contracting parties indemnify each other that the execution of this
Agreement does not entail intermediation fees, commissions or other payment
claims from third parties, which should be borne by the possibly requesting
contracting party.

5.            
Partial nullity, regulatory gaps, construction

a)            
When any present or future clauses of this Agreement become legally invalid in
full or in part, or are unenforceable, or further lose their legal validity or
enforceability, the validity of all other clauses hereof shall not be affected.
This is also applicable if this Agreement is found to have gaps.

b)            
The invalid or unenforceable clause should be replaced by or the gap should be
filled with an appropriate valid clause the parties would have agreed upon, if
upon conclusion hereof they had paid heed thereto. This is also applicable when
the invalidity of one clause is due to the service volume or time (deadline,
interval) set forth hereunder; in such cases, a service volume or time
(deadline, interval) shall apply instead, as are legally allowed, as closest as
possible to the will of the parties.

c)            
If the validity of one clause as described above can be ensured only by
agreement, in compliance with certain special formal conditions, the parties are
bound to perform the necessary operations and make the relevant statements.

	Davos, March 16th, 2005 
	Seller................ 	/s/ Hans-Jürgen Kistler
  
	  	Chairman of the Board of
      Directors 
	  	 
	Hanover, 31.03.2005 	 
	Buyer............. 	/s/ Horst Rose                                                         /s/
      Martin Steiner 
	  	Geschäftsführer/COO                                          Geschäftsführer/CEO
    
	  	  
	Appendix 1: Patent Registration 
	  	  
	Appendix 2 includes: 	Confirmation by the registering
      persons that all rights related to the 
	  	registrations of patents WO
      2004/094639 A2 and GB 0309345.7 have been 
	  	assigned to Productomics AG.
  

(The two appendices mentioned are the last English pages from
  the PDF scan.)

7Filed by Automated Filing Services Inc. (604) 609-0244 - Imvision Therapeutics Inc. - Exhibit 10.6

EXHIBIT 10.6

M A S T E R   S E R V I C E S   A G R E E
M E N T

THIS AGREEMENT is entered into BY and BETWEEN 

ImVisioN GmbH, a company duly
existing and organised under the laws of the Federal Republic of Germany and
having its registered offices at Feodor-Lynen-Str. 5, 30625 Hannover, Federal
Republic of Germany 

- hereinafter referred to as "SPONSOR" -

and 

Institut für klinische Forschung und
Entwicklung (IKFE) GmbH, a company duly existing and organised under the
laws of the Federal Republic of Germany and having its registered offices at
Parcussstraße 8, 55116 Mainz, Federal Republic of Germany 

- hereinafter "IKFE" -

	WHEREAS, 	
      SPONSOR intends to conduct a clinical development program
      for a vaccine for desensitization of patients with cat dander allergies
      based on its proprietary MAT- technology 

	  	
      

	WHEREAS, 	
      IKFE offers services as 

	a contract research organisation, hereinafter CRO IKFE
  
	a central laboratory, hereinafter LABORATORY
  
	a clinical site for occasional study purposes, hereinafter CLINIC
  
	a regulatory group, hereinafter REGULATORY 

WHEREAS, SPONSOR wishes to contract services offered by
IKFE and IKFE is willing and able to perform the services contracted by SPONSOR.

NOW, THEREFORE, the parties hereby agree as follows: 

Sec.1 
Subject Matter

	1. 	
      The subject of this Agreement is the regulatory and
      clinical trial support for the clinical product development of a
      desensitization vaccine for cat dander allergy based on SPONSOR’s
      proprietary MAT technology in accordance but not limited to the clinical
      development plan as attached hereto as Attachment 1 (hereinafter
      referred to as "STUDY PLAN"). The STUDY PLAN describes all projects to be
      performed in the development that are subject of this
  Agreement.

	Page 1 of 17 

	2. 	
      CRO IKFE provides its professional services as
      independent contract research organisation for the STUDY PLAN on behalf of
      SPONSOR.

	 	 
	3. 	
      CLINIC will participate in the planned studies under the
      STUDY PLAN as agreed between IKFE and SPONSOR.

	 	 
	4. 	
      LABOARATORY shall perform safety and efficacy
      measurements of studies under the STUDY PLAN in compliance with the
      standards of GLP and its accreditation by the College of American
      Pathologists.

	 	 
	5. 	
      REGULATORY will provide regulatory support and consulting
      services to obtain all regulatory approvals neccessary for the conduct of
      the the studies under the STUDY PLAN.

	 	 
	6. 	
      The parties of this Agreement shall mutually act as
      independent contractors. Neither party shall have the authorization to
      bind or act on behalf of the other party without its prior written
      consent.

Sec.2
Term/ Time Schedule /Termination

	1. 	
      This Agreement shall become effective and binding by
      March 1st 2005 upon the signatures of both parties.

	 	 
	2. 	
      The time schedule for the conduct of services by IKFE
      shall be agreed by the parties as follows:

	Task 	Start Date 	End Date 
	
Regulatory Activities: 
Regulatory support
      
Consultance 
	
March 2005 

	
Completion of the STUDY PLAN 

	
CRO activities: 

e.g. Clinical trial conduct 
and
      Tracking, Data 
management 	
April 2005 

	
Completion of the STUDY PLAN
  

  

  	Page 2 of 17 

	LAB activities: 

Implementation of efficacy
      
measures 	Start of the first project requiring
      
laboratory support as defined in 
the STUDY PLAN 
	Completion of the STUDY PLAN 

	
Clinic activities: 

Conduct of clinical studies
      
as investigative site 	
Start of the CAT-02 study in 
which CLINIC
      participates as 
investigator 
	
Completion of the STUDY PLAN

	4. 	
      Sponsor shall have the right to terminate this Agreement
      by three (3) months prior written notice. In case of termination by
      Sponsor IKFE shall be entitled to demand compensation payments of 25 % of
      the remaining budget at the time of such termination as defined in the
      WORK ORDER. The WORK ORDER provides details for the conduct of a specific
      subproject as part of the STUDY PLAN (e.g. study CAT-001, study CAT-002,
      or regulatory consultance) (see also sect. 6).

	 	 
	5. 	
      The right of either party to immediately terminate this
      Agreement by written notice by cause shall remain unaffected. Such cause
      shall be: but not limited to - (a) the respective regulatory body
      recommends to finish the clinical development program or (b) one party
      breaches its main obligation under this agreement and does not rectify
      such infringement within thirty (30) days after the receipt of a written
      demand letter sent from the other party.

	 	 
	6. 	
      In the event that SPONSOR will be in arrears with payment
      IKFE shall be entitled to stop further services in the study.

	 	 
	7. 	
      After the termination of this Agreement, each and any
      party is obliged to fulfil its obligations which have already become due
      prior to the date of termination.

Sec.3
Scope of CRO IKFE Services

	1. 	
      CRO IKFE assures that its Standard Operating Procedures
      ("SOP") meet the GCP standards.

	 	 
	2. 	
      CRO IKFE shall prepare, manage and conduct the STUDY PLAN
      according to all applicable laws, regulations, to each current applicable
      common standards as defined for by the conventions “the revised
      Declaration of Helsinki” and the “Guidelines on Good Clinical Practice
      ("GCP") Act”. These shall abide at least to its own SOPs. CRO IKFE shall
      be liable for the conduct of its obligations hereunder by its employees
      and by its appointed clinical research associates ("CRA") and by any third
      party retained by CRO IKFE.

	Page 3 of 17 

	 3. 	 CRO IKFE shall ensure that timelines and
        cost estimate are met, quality objectives are achieved and on-going communications
        with SPONSOR are maintained. In the event of changes of time schedule
        and agreed amount of costs, CRO IKFE is obliged to inform SPONSOR timely
        in written form. In the case of increase of cost budget, CRO IKFE shall
        provide SPONSOR with its cost estimate before CRO IKFE fulfils its services
        and shall request the SPONSOR to accept each additional cost estimate
        in writing.

	 	 	 
	 4. 	 CRO IKFE shall take care of the preparation
        of study documents, such as case report forms ("CRF"), patient informations
        and other study related documents needed for regulatory approval as set
        forth in the appropriate regulatory guidelines for conduct of clinical
        studies..

	 	 	 
	 5. 	 WORK ORDERS including budgets and time lines
        will be prepared for each clinical research project of the STUDY PLAN.
        CRO IKFE shall conduct all studies as agreed in separate budget sheets
        for each budget in compliance with all items given therein.

	 	 	 
	 6. 	 CRO IKFE shall be liable for its employees,
        CRAs, and other third parties appointed for the execution of services
        by CRO IKFE in connection with the STUDY PLAN.

	 	 	 
	 7. 	 SPONSOR and CRO IKFE will recruit clinical
        investigator(s). CRO IKFE shall take care that such recruited clinical
        investigator(s) will also conduct their work in accordance with all applicable
        laws and regulations, with commonly accepted conventions such as the Revised
        Declaration of Helsinki as well as with the GCP- guidelines in each current
        applicable version. In case of non-compliance CRO IKFE will inform SPONSOR
        immediately in writing about this situation together with the planned
        corrective measures.

	 	 	 
	 8. 	 CRO IKFE will on behalf of SPONSOR prepare
        necessary and appropriate documentation for submission to the appropriate
        regulatory authority and IEC to obtain all necessary approvals for conducting
        the STUDY PLAN as part of the REGULATORY work. CRO IKFE shall set up

	 	 	 
		 (i) 	 the Study Master Files according to the applicable
        SOPs

		 (ii) 	 obtain all relevant "critical" documents for the trials

		 (iii) 	 design an appropriate Critical Documents Receipt List
        as a supporting instrument for the CRAs

		 (iv) 	 review, approve or reject all incoming investigator
        documents according to GCP and individual requirements as demanded by
        CRO IKFE file maintenance.

		 (v) 	 proper filing of all incoming papers (investigator
        documents, site visit reports etc.) and file audits to assure the completeness
        of the documents and to identify missing documents.

	Page 4 of 17 

	9. 	 CRO IKFE shall provide SPONSOR with each and every documentation
        in timely order to meet with the time schedule as set forth under the
        STUDY PLAN and the WORK ORDERS.

	 	 
	10. 	 Initial approvals by the Ethics Committee and each subsequent
        approval to be granted by the Ethics Committee shall be submitted by CRO
        IKFE. CRO IKFE on behalf of SPONSOR will also take care for Ethics Committee
        interactions such as finalization of the informed consent form and patient
        inform sheet, document compilation and submission and necessary study
        updates.

	 	 
	11. 	 REGULATORY on behalf of SPONSOR will prepare and provide
        CRO IKFE with regulatory and IEC - documents.

	 	 
	12. 	 CRO IKFE shall appoint its Project Manager for the STUDY
        PLAN who shall be the primary contact at CRO IKFE for the term of the
        STUDY PLAN and shall inform SPONSOR about the name and contacting address
        of the Project Manager. However, CRO IKFE shall be solely responsible
        to

	 	 
	 		set- up and develop project management tools
        
	develop and maintain project plans and ensure that milestones are
          met
        
	ensure that investigator trainings takes place
        
	proactively identify and resolve critical issues
        
	prepare and track detailed timelines to meet the time schedule
        
	ensure appropriate and continuous resource allocation
        
	co-ordinate kick-off meeting and study-specific project team-meetings,
          if any
        
	oversee the generation of monitoring guidelines and study manuals
          to ensure consistency of work across the study
        
	maintain project working file
        
	ensure effective communication and distribution of project information
          between departments
        
	render periodic status reporting on a monthly basis to SPONSOR and,
          if any, project team in accordance with SPONSOR's requirements. 

	 	 

	13. 	
      CRO IKFE shall be liable for all administrative tasks
      arising out of or in connection with the management of the studies under
      the STUDY PLAN, including but not limited to the preparing of Study Master
      File and Trial Investigator File copying, filing, typing, etc and may
      appoint and/ or retain Clinical Monitoring Associates
  ("CMAs").

	Page 5 of 17 

	14. 	 Completed CRFs received from the trial centres, ancillary
        CRF pages, adverse event documentation, and patient-specific correspondence
        shall be processed and tracked by CRO IKFE. CRO IKFE shall be liable for
        the correct page-by-page entry of CRFs according to SDV guidelines set
        up in the protocol and answered data queries into a computerized tracking
        system.

	 	 
	15. 	 CRO IKFE shall ensure that any investigator conducting
        a study under the STUDY PLAN has all required qualifications and that
        the investigators are aware of their regulatory obligations to provide
        periodic progress reports to the Ethics Committee, and to obtain renewals
        of the protocol approval according to the requirements of the Ethics Committee.
        CRO IKFE shall also review with the investigators their requirement to
        provide SPONSOR and relevant regulatory authorities with full and open
        access (as permitted by local regulations) to all source documents.

	 	 
	16. 	 Should appropriate regulatory authorities or any other
        federal, state or local government authority conduct, or give notice of
        intent to conduct, an inspection at any trial centre or take any other
        regulatory action with respect to services provided for in this Agreement,
        then CRO IKFE shall without undue delay give SPONSOR notice thereof, supply
        all information pertinent thereto, and SPONSOR shall have the right, but
        not the obligation, to be present at any such inspections or regulatory
        action.

	 	 
	17. 	 CRO IKFE may perform interim monitoring visits to confirm
        that the investigators are conducting a study under the STUDY PLAN in
        compliance with the protocol, the GCP Guidelines and applicable regulations,
        and to reconfirm the continued adequacy of trial centre personnel. SPONSOR
        shall have the right, but not the obligation, to monitor and/or audit
        a study under the STUDY PLAN from time to time with respect to services
        of CRO IKFE provided hereunder. Upon request of SPONSOR, CRO IKFE shall
        assist and co-operate with SPONSOR therein. Interim monitoring visits
        will be performed after mutual agreement of SPONSOR and the CRO IKFE.

	 	 
	18. 	 CRO IKFE may perform during such interim monitoring
        visits source document verification of CRF data for accuracy and completeness
        and will also review source data for appropriate identification, documentation,
        and reporting of both serious and non-serious adverse events. CRO IKFE
        shall also review the regulatory binder.

	 	 
	19. 	 After each trial centre visit, CRO IKFE shall complete
        a written report that includes protocol violations or deviations observed,
        both serious and non-serious adverse events, patient screening and enrolment
        data, and other pertinent information. In the event of serious and/or

	Page 6 of 17 

		
      unexpected adverse events in the course of a study under
      the STUDY PLAN, SPONSOR - shall be informed within a period of twenty-four
      (24) hours after CRO IKFE has received the information.

	 	 
	20. 	
      CRO IKFE shall keep SPONSOR continuously informed on the
      progress of the studies under the STUDY PLAN.

	 	 
	21. 	
      CRO IKFE shall contact each and any trial centre on a
      regular basis following trial centre initiation, in order to obtain
      updated status information from investigators, discuss any issues and help
      encourage recruitment. Written narratives or minutes of all such
      conversations shall be placed in the Study Master File and each respective
      Investigator's File.

	 	 
	22. 	
      CRO IKFE shall complete monitoring, data collection and
      review, processing as defined herein and in the Study Protocols and as
      otherwise required by SPONSOR. CRO IKFE shall store copies of all data and
      records in accordance with all applicable provisions and
    regulations.

	 	 
	23. 	
      CRO IKFE shall take care that all clinical laboratory
      tests that are to be conducted shall be appropriately approved as required
      at CRO IKFE and performed in accordance with the CAP and ISO requirements
      at LABORATORY.

	 	 
	24. 	
      CRO IKFE will perform data management. This includes
      database design (based on Microsoft Access), database clearance and
      database lock two months after last patient out. CRO IKFE will be
      responsible for data capture, data entry, query handling, and data
      evaluation

Sec. 4 
Scope of CLINIC

General

CLINIC will serve on an agreed basis as clinical investigative
site for the CAT-02 study under the STUDY PLAN or any other clinical part of the
development program if necessary and agreed.

	1. 	
      Prior to the enrollment of any subject the investigator
      at CLINIC is obligated to inform the patient of the nature, scope and
      possible consequences of the clinical trial and to obtain the informed
      consent of the patient in accordance to the § 40 AMG and in compliance to
      the above cited principles of a duly executed clinical trial. Before start
      of the study the positive vote of the ethical committee must be obtained
      in regards to the study protocol and patient informed consent. Possible
      amendments to the protocol are subject to approval by the ethical
      committee.

	Page 7 of 17 

	2. 	
      The investigator at CLINIC has to be qualified by
      education, training, and experience to assume responsibility for the
      proper conduct of the trial, and has to provide evidence of such
      qualifications in an up-to-date curriculum vitae. Where applicable the
      investigator at CLINIC may secure necessary clinical expertise by
      appointing competent employees.

	 	 
	3. 	
      In agreement with the SPONSOR the investigator at CLINIC
      may delegate the execution of this trial to a co-investigator. The
      co-investigator should be qualified by education, training, and experience
      to assume responsibility for the proper conduct of the trial, and has to
      provide evidence of such qualifications in an up-to-date curriculum
      vitae.

	 	 
	4. 	
      The investigator at CLINIC affirms that he has read and
      understood the documents in regard to the study medication supplied by CRO
      IKFE including the potential risks and side effects in connection with the
      application of the study medication.

	 	 
	5. 	
      The investigator at CLINIC will document every adverse
      event in the “Adverse Event” Case Report Form. As stipulated in the
      protocol every serious adverse event must be reported immediately to CRO
      IKFE. In accordance to the § 40 AMG CRO IKFE will report every “Serious
      Adverse Event” to the ethical committee and the appropriate regulatory
      authorities.

	 	 
	6. 	
      The guidelines of “Good Clinical Practice (GCP)” provide
      for reviews in which the data collected during the study is verified with
      the original patient data (source data). Given the prior written consent
      of the patient the investigator at CLINIC agrees for this purpose, to give
      an authorized and bound-to-secrecy representative of CRO IKFE, SPONSOR
      appointed representative, consignee (Monitor) or authorized individuals of
      national and foreign health authorities access to patient data. The
      investigator at CLINIC is obligated to ensure that he himself, or one of
      his assigned employees is present during such a monitoring visit to review
      and discuss the further process of a study under the STUDY PLAN as well as
      to discuss any data relevant for a study under the STUDY PLAN.
      Additionally, the investigator at CLINIC agrees that a civil servant of
      the appropriate regulatory authority has the right within their bounds of
      responsibility to audit the investigator. Patient related data will be
      forwarded to CRO IKFE in anonymous form only. Prior signed informed
      consent of the patient is mandatory if the exceptional case might arise to
      forward personal data. Laboratory inspections to verify “Good Laboratory
      Practice” can also take place.

CLINIC furthermore agrees at all times:

	 	1. 	 To collect and process Trial Data in accordance with
        the provisions of this Agreement or

	Page 8 of 17 

			 as otherwise instructed by the SPONSOR from time to
        time;

	 	 	 
	 	2. 	 To ensure that it does not collect any data relating
        to individuals other than the categories of data specified in the Protocol;

	 	 	 
	 	3. 	 To collect and process Trial Data solely for the purposes
        of the Trial and in the manner specified in the Protocol and not further
        to process such data in any other manner;

	 	 	 
	 	4. 	 To ensure that all Trial Data are accurate and, where
        necessary, kept up to date and to use best efforts to ensure that Trial
        Data which are inaccurate or incomplete are erased or rectified;

	 	 	 
	 	5. 	 To ensure that the technical and organizational measures
        specified in the Protocol are taken to protect Trial Data against accidental
        or unlawful destruction or accidental loss or damage, alteration, unauthorized
        disclosure or access and against all other unauthorized disclosure or
        access and against all other unauthorized or unlawful forms of processing.

Sec. 5
Scope of LABORATORY

LABORATORY will provide the services (“Services”) more
specifically described in a project plan entitled “WORK ORDER” for each of the
clinical projects defined in the STUDY PLAN.

LABORATORY will perform the Services in accordance with
generally accepted professional standards, including but not limited to, the
current state of the laboratory art as well as standards designated by SPONSOR.
LABORATORY will comply with national, state and local laws, regulations and
standards as considered to be applicable to the Services. LABORATORY will
appoint a Quality Assurance Monitor for the Services who shall monitor the
Services for conformance to applicable government regulations and standard
operating procedures.

LABORATORY will use the same test methodology for the duration
of the STUDY PLAN. If LABORATORY releases new methodology, it shall notify
SPONSOR. SPONSOR, at its option, may accept the use of the new methodology
provided LABORATORY shall not institute the new methodology until its use is
approved in writing by SPONSOR.

LABORATORY shall retain all specimens for the duration of the
  STUDY PLAN. Specimens can not be discarded by LABORATORY without SPONSOR’s
  written permission at any time 

	Page 9 of 17 

LABORATORY will provide the results to SPONSOR, CLINIC,
REGULATORY and CRO IKFE after measurements.

  [X] By hard copy spreadsheet at completion of all analyses 

  [X] Electronically by spreadsheet at completion of all analyses 

  [X] By spreadsheet on CD at completion of all analyses

Sec. 6 
Scope of REGULATORY

REGULATORY shall assist and support Sponsor in the performance
of all work related to the regulatory requirements related to the STUDY
PLAN.

This includes, but is not limited to:

	 	-	preparation of regulatory documents 
	 	-	participation in meetings with regulatory agencies 
	 	-	performance of audits 
	 	-	presentations at company meetings and presentations to the
      financial community 

Payments for this activity will be clarified in the WORK
ORDER“Regulatory Support”

Sec. 6
Description of a WORK ORDER

Each WORK ORDER shall contain a general description of the
work to be performed (e.g. study synopsis) and the start date and duration of a
project. In case of a clinical study project, the following information will
be provided in the WORK ORDER

	
    Definition and budget for pre-study activities including but not limited
      to: protocol preparation, study document preparation, submission to IRBs
      and authorities, patient insurance, investigator selection and pre-study
      visits, laboratory kit preparation, start-up visits 

  
	
    Definition and budget for study activities including but not limited to:
      investigator fees, patient fees, laboratory fees, shipments, monitoring,
      device and study material costs 

  
	
    Definition and budget for post-study activities including but not limited
      to: data management, data base creation, data analysis, statistical report,
      final study report, publications and abstracts for scientific meetings 

  

	Page 10 of 17 

Sec. 7
Data maintenance and Reporting:

CRO IKFE and IKFE management shall keep and maintain the
complete clinical development data base and shall act on behalf of SPONSOR and
in representation of SPONSOR as communication partner for all clinical and
regulatory issues related to the STUDY PLAN. 

Sec. 8 
Secrecy Obligation

	1. 	 Both parties agree that confidential information will
        be exchanged bi-directionally in the course of the clinical development.
        They undertake to hold any and all information transmitted in conjunction
        with the STUDY PLAN (hereinafter the "Information") in strict confidence
        and to use it exclusively for the purpose of this Agreement. IKFE shall
        further keep the Information and any knowledge gained from or connected
        with the Information and the study projects in strict confidence and neither
        directly nor indirectly make use of them. It is agreed that all data generated
        during this study is the exclusive intellectual property of the SPONSOR
        and that disclosure of this intellectual property would be considered
        extremely detrimental to the business of the SPONSOR.

	 	 
	2. 	 Both parties may disclose the Information to employees
        onIy if it is necessary for the purpose of this Agreement; prior to the
        disclosure the secrecy provisions stipulated herein shall be imposed on
        the employees accordingly.

	 	 
	3. 	 The secrecy obligation of the parties shall not apply
        to

	 	 
	 		
          Information which, after disclosure, becomes part of the public domain
            by publication or otherwise, expect directly or indirectly by breach
            of this Agreement by the parties; 

        
	
          Information which the parties can prove to be already known or developed
            independently by the parties at the time of disclosure by SPONSOR;
          

        
	
          Information which the parties lawfully receives from a third party.
          

        

	 	 

	4. 	
      The parties may disclose Information to a legally
      constituted authority if this is required by laws of the applicable
      jurisdiction or if it is necessary for the purpose of this Agreement. In
      such

	Page 11 of 17 

		
      case the respective party shall inform the authority
      about the confidential character of the Information and about which
      documents made available to the authority are affected.

	 	 
	5. 	
      The secrecy obligation shall be valid for an unlimited
      period of time.

	 	 
	6. 	
      The aforementioned secrecy obligation shall apply
      accordingly to the Clinical Supplies or other material used in any study
      under the STUDY PLAN, IKFE has received from
SPONSOR.

Sec. 9 
Remuneration

	1. 	
      SPONSOR shall pay to IKFE fees for all services arising
      out of or in connection with the STUDY PLAN and performed by the involved
      IKFE departments pursuant to this Agreement the amounts that will be given
      in the WORK ORDERS. When used in the WORK ORDERS, "pass-through costs"
      (e.g. travel expenses, costs of external vendors) shall mean all necessary
      costs actually incurred by IKFE in due diligent execution of its
      obligations hereunder in order to expedite successful completion of the
      studies under the STUDY PLAN if such costs are in line with the usual
      market conditions within Germany.

	 	 
	2. 	
      SPONSOR shall pay to the IKFE fees for all previously
      agreed services – if not recorded in the responsibility split contract and
      descript in the signed budget - arising out of or in connection with the
      studies under the STUDY PLAN and performed by the IKFE. These fees would
      be charged after written arrangement and on the basis of hourly rates, as
      listed in the budget.

	 	 
	3. 	
      SPONSOR shall render initial payments to IKFE as defined
      and agreed upon in the WORK ORDER, which become due and payable upon the
      conclusion of the WORK ORDER and upon the submission of the respective
      invoice from IKFE to SPONSOR. Payments subsequent to the initial payment
      shall become due upon the submission of each respective monthly invoice
      and shall be based on the progress of the work and on the payment schedule
      as agreed in the WORK ORDERS.

	 	 
	4. 	
      All payments shall be made within thirty (20) days upon
      receipt of each respective invoice by SPONSOR from IKFE.

	 	 
	5. 	
      SPONSOR and IKFE shall have to agree in writing on any
      increase or decrease of IKFE's fees respectively on any fees for services
      of CRO, CLINIC, REGULATORY and/or LABORATORY.

	Page 12 of 17 

Sec. 10 
Indemnity

	1. 	 IKFE shall conclude an appropriate subject liability
        insurance on behalf of all patients participating in a study under the
        STUDY PLAN which will meet the requirements set forth under § 40
        – 42 of the German AMG. The costs for this insurance will be covered
        by SPONSOR.

	 	 
	2. 	 IKFE shall indemnify, defend and hold SPONSOR, its affiliates,
        agents and employees safe and harmless against any and all loss, cost,
        claims, actions, liability and/or suits (including attorneys' fees) suffered
        or incurred as a result of personal injury to a patient or any third party
        participating in a study under the STUDY PLAN or otherwise incurred in
        connection with a study under the STUDY PLAN beyond the sphere of SPONSOR's
        liabilities.

	 	 
	3. 	 SPONSOR shall indemnify, defend and hold IKFE, its affiliates,
        agents, servants and employees safe and harmless against any and all loss,
        cost, claims, actions, liability and/or suits (including attorneys' fees)
        suffered and incurred as a result of personal injury to a patient participating
        in a study under the STUDY PLAN directly caused by the Clinical Supplies
        of SPONSOR in connection with the studies under the STUDY PLAN beyond
        the sphere of IKFE's liabilities, provided that,

	 	 
	 		
          the applicable statutory regulations as well as the standards provided
            for in the generally accepted conventions as mentioned in Sec.4 para.
            1 of this Agreement have been met; 

        
	
          the patient in the Studies has been informed about the existence
            of the aforementioned insurance; 

        
	
          SPONSOR has been notified promptly by IKFE of any information related
            to its Clinical Supplies in connection with a study under the STUDY
            PLAN and the injury to health; 

        
	
          SPONSOR is given control over the conduct and disposition on the
            claim or lawsuit; 

        
	
          SPONSOR receives the full support of the clinical investigator(s)
            and IKFE in a legal dispute outside the competent courts and during
            a lawsuit before competent courts. 

        

Sec. 11

  Ownership I Property Rights

  

	Page 13 of 17 

All materials, documents, information and suggestions of every
kind and descriptions supplied to IKFE by SPONSOR or prepared or developed by
IKFE pursuant to this Agreement shall be the sole and exclusive property of
SPONSOR and SPONSOR shall have the right to make whatever use if it seems
desirable of any such materials, documents and information. Unless otherwise
required by law or by the terms of this Agreement, all such SPONSOR property
shall be returned by IKFE to SPONSOR immediately after the termination of this
Agreement without any demand of SPONSOR. 

Sec. 12
Patent Rights, Publication

	1. 	
      The legal situation with respect to patents of the
      parties possibly existing at the time of signing of this Agreement shall
      remain unaffected.

	 	 
	2. 	
      IKFE shall ensure that all rights to its employees’
      inventions, discoveries or improve-ments arising in connection with the
      performance of this Agreement will be fully assigned to IKFE and IKFE
      shall transfer all rights to SPONSOR to the effect that SPONSOR have the
      exclusive, transferable, unlimited, world-wide right free-of-charge and
      without any remuneration to the inventors to use and to exploit the
      invention, discovery or improvement in any way whatsoever. Patent
      applications will be filed in SPONSOR’s name and at its costs mentioning
      the persons as inventors who have made the invention(s) and have been
      named by IKFE in writing. IKFE will comply with all formalities and
      requirements necessary to obtain a patent. IKFE will assist SPONSOR to
      obtain patent(s) for instance by giving SPONSOR its comments and advice in
      connection with preparation of the specification and claims or office
      actions etc. In case that a granted patent concerning the invention(s)
      will be exploited commercially by SPONSOR, the invention(s) will be
      remunerated by SPONSOR according to the German employees inventions law
      ("Arbeitnehmererfindungsgesetz") in case of involvement of IKFE employees
      in the invention.

	 	 
	3. 	
      To secure patent applications, in particular to establish
      a priority, IKFE shall ensure that all necessary documents and
      information, as well as the necessary declarations of the inventors will
      be made available to SPONSOR without delay.

	 	 
	4. 	
      Upon request of SPONSOR, IKFE shall ensure that any and
      all applications, assignments or other instruments will be executed and
      any testimony will be given as SPONSOR deems necessary to apply for and
      obtain letters of patent in any country or to protect otherwise SPONSOR's
      interests therein.

	 	 
	5. 	
      IKFE shall refrain from publishing any information,
      declaration, invention or whatsoever arising

	Page 14 of 17 

out of or in connection with the STUDY
PLAN without the prior written consent of SPONSOR.

Sec. 13 
Miscellaneous

	1. 	
      This Agreement constitutes the entire agreement of the
      parties with respect to the subject matter hereof, and supersedes all
      previous agreements as well as proposals or offers irrespective of whether
      oral or written, and all negotiations, conversations or discussions
      between the parties related to this Agreement.

	 	 
	2. 	
      This Agreement shall not be assigned wholly or in part to
      third parties or to any legal successors by either party without the prior
      written consent of the other party.

	 	 
	3. 	
      All notices given by either party to the other pursuant
      to this Agreement shall be in writing to be valid.

	 	 
	4. 	
      The waiver of and relief from any breach or
      non-fulfilment of any term and condition of this Agreement does not
      constitute a waiver of and relief from any other breach or non- fulfilment
      of that or any other term and condition.

	 	 
	5. 	
      If the fulfilment by any party hereto or any of its
      obligations hereunder is prevented by Force Majeure, then such party shall
      be excused from its obligations hereunder in as far as its obligations are
      affected and for so long as such prevention, restriction or interference
      remains in force plus a period of thirty (30) days.

	 	 
	6. 	
      In the event of any provisions of this Agreement being or
      becoming ineffective or of any omission being discovered, the
      effectiveness of the remaining provisions shall not thereby be affected.
      In place of the ineffective provisions or for the purpose of rectifying
      the omission, a reasonable arrangement shall operate, being the nearest
      legally possible approach to that which the parties hereto desired or
      would have desired in consideration of the spirit and object of this
      Agreement had they considered such matter.

	 	 
	7. 	
      Amendments to this Agreement, modifications and
      additional agreements, require the written form. The same applies to
      changes regarding the requirement of written form.

	 	 
	8. 	
      The Exhibits form an integral part of this
    Agreement.

	Page 15 of 17 

	9. 	
      This Agreement shall be governed and construed under the
      laws of the Federal Republic of Germany without any reference to the
      German regulations and rules on the Conflict of Laws.

	 	 
	10. 	
      Place of venue in case of legal conflict shall be the
      place of the sewed party.

IN WITNESS WHEREOF, this Agreement shall be executed by
signature of the legal representatives of each party in two counterparts in the
English language, and each such counterpart shall be deemed an original
hereof.

 

 

	Date: 19.05.2005 	  	Date: 02.05.2005 
	  	  	  
	  	  	  
	  	  	  
	/s/ Martin Steiner                        /s/
      Horst Rose 	 	/s/ Andreas Pfützner 
	Geschäftsführer/CEO          Geschäftsführer/COO
      	 	Managing Director
	SPONSOR 	  	IKFE GmbH 

	Page 16 of 17 

EXHIBIT 1 / STUDY PLAN

  

	Page 17 of 17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}]]